Readoutin 135d
MediciNova — MN-166
Phase 3 primary completion: Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS.
- Date
- Apr 2027
- Type
- Readout
- Indication
- Amyotrophic Lateral Sclerosis
Readoutin 135d
Phase 3 primary completion: Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.